AMOYTOP(688278)2024-10-24 09:17Financial Performance - The company's revenue for Q3 2024 reached ¥764,896,594.85, representing a year-over-year increase of 37.52%[2] - Net profit attributable to shareholders for Q3 2024 was ¥249,807,349.38, up 49.83% compared to the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.61, reflecting an increase of 48.78% year-over-year[2] - Total operating revenue for the first three quarters of 2024 reached CNY 1,954,701,664.76, a 34% increase from CNY 1,459,790,700.44 in the same period of 2023[15] - Net profit attributable to shareholders of the parent company was CNY 554,149,217.81, up 50% from CNY 368,906,357.86 year-on-year[16] - Basic and diluted earnings per share for the period were CNY 1.36, compared to CNY 0.91 in the previous year[17] - The company reported a gross profit of CNY 655,584,548.33, up from CNY 463,676,112.60, reflecting a growth of 41%[15] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥2,683,315,614.46, a 13.89% increase from the end of the previous year[3] - The total equity attributable to shareholders increased by 20.69% to ¥2,264,547,960.53 compared to the previous year[3] - The company's total liabilities increased to RMB 1,509,551,461.82, compared to RMB 1,340,191,036.92, indicating a growth of around 12.5%[12] - Total liabilities decreased to CNY 418,767,653.93 from CNY 479,685,751.45, reflecting a reduction of approximately 12.7%[14] - Non-current liabilities totaled CNY 69,465,147.23, down from CNY 76,028,137.24, indicating a decrease of about 8.2%[14] Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 23.75% to ¥292,015,044.33[2] - In the first three quarters of 2024, the cash inflow from operating activities reached ¥1,922,798,869.91, a significant increase from ¥1,530,035,737.29 in the same period of 2023, representing a growth of approximately 25.6%[18] - The net cash flow from operating activities for Q3 2024 was ¥292,015,044.33, compared to ¥382,951,697.45 in Q3 2023, indicating a decrease of about 23.7%[19] - The cash outflow for operating activities totaled ¥1,630,783,825.58 in Q3 2024, up from ¥1,147,084,039.84 in Q3 2023, reflecting an increase of approximately 42.1%[19] - The cash and cash equivalents at the end of Q3 2024 were ¥332,950,167.74, down from ¥524,889,447.27 at the end of Q3 2023, indicating a decrease of approximately 36.5%[20] - The company experienced a net decrease in cash and cash equivalents of ¥79,700,777.52 in Q3 2024, contrasting with a net increase of ¥224,558,411.01 in Q3 2023[20] Research and Development - Research and development expenses totaled ¥89,136,009.28 in Q3 2024, which is a 24.33% increase compared to the same period last year[3] - Research and development expenses increased to CNY 193,341,950.18, a rise of 35% from CNY 142,861,485.40 in the previous year[15] Future Plans - The company plans to continue expanding its product offerings and enhancing its market presence, particularly in the hepatitis treatment sector[6] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[15] Donations and Subsidies - The company received government subsidies amounting to ¥4,564,816.51 during Q3 2024, contributing to its financial performance[4] - The company made a cash donation of RMB 2 million towards the "China Chronic Hepatitis B Clinical Cure (Everest) Project" during the reporting period[11] - The company has committed an additional RMB 8 million to the same project, with payments scheduled over four installments[11]